Patrick R. O'Neil sold $242k of IONS
EVP CLO & General Counsel at IONIS PHARMACEUTICALS INC. 7,360 shares at an average of $32.83, traded Jan 16, 2025, filed Jan 17, 2025.
Score components
- +15RoleOfficer
- +13Trade size$242k at market
- +5Share of holdings soldSold 11% of holdings
- +15Cluster10 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000874015-25-000063, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 15, 2025 | MOption exercise Common Stock | +19,690 | $0.00 | $0 | 68,563 | Jan 17, 2025 |
| Jan 16, 2025 | SOpen-market sale Common Stock | -7,360 | $32.83 | $242k | 61,203 | Jan 17, 2025 |
| Jan 15, 2025 | AGrant or award Performance Restricted Stock Unitsderivative | +22,000 | $0.00 | $0 | 64,801 | Jan 17, 2025 |
| Jan 15, 2025 | AGrant or award Restricted Stock Unitderivative | +33,000 | $0.00 | $0 | 80,414 | Jan 17, 2025 |
| Jan 15, 2025 | MOption exercise Restricted Stock Unitderivative | -19,690 | $0.00 | $0 | 60,724 | Jan 17, 2025 |
Related signals
Other insiders at IONIS PHARMACEUTICALS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 5Weak | IONIS PHARMACEUTICALS INC | Patrick R. O'Neil EVP CLO & General Counsel | $110k 1,700 shares | -3% | |
| 26Weak | IONIS PHARMACEUTICALS INC | Joseph Baroldi EVP, Chief Business Officer | $743k 11,950 shares | -27% | |
| 30Weak | IONIS PHARMACEUTICALS INC | Patrick R. O'Neil EVP CLO & General Counsel | $1.4M 21,000 shares | -27% | |
| 25Weak | IONIS PHARMACEUTICALS INC | C Frank Bennett EVP, Chief Scientific Officer | $358k 6,000 shares | -7% | |
| 0Weak | IONIS PHARMACEUTICALS INC | Joseph Baroldi EVP, Chief Business Officer | $16k 250 shares | -1% | |
| 30Weak | IONIS PHARMACEUTICALS INC | C Frank Bennett EVP, Chief Scientific Officer | $2.3M 38,909 shares | -42% | |
| 40Moderate | IONIS PHARMACEUTICALS INC | Joseph Baroldi EVP, Chief Business Officer | $1.9M 32,800 shares | -94% | |
| 12Weak | IONIS PHARMACEUTICALS INC | Shannon L. Devers EVP, Chief Human Resources Ofc | $193k 3,162 shares | -17% | |
| 33Weak | IONIS PHARMACEUTICALS INC | Richard S Geary EVP, Chief Development Officer | $504k 10,000 shares | -11% | |
| 30Weak | IONIS PHARMACEUTICALS INC | Eugene Schneider EVP, Chf Clinical Develop Ofcr | $1.2M 19,658 shares | -28% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.